Formamide, N,N-dimethyl-, hydrofluoride Cas:61856-32-4

We are Formamide, N,N-dimethyl-, hydrofluoride CAS:61856-32-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Formamide, N,N-dimethyl-, hydrofluoride

Synonyms:
N,N-dimethylformamide,hydrofluoride
 
Molecular Formula: C3H8FNO
Molecular weight:93.10010
 
 
 
Our company is committed to establishing a complete fluorochemical products and technology platform to provide customers with convenient one-stop services. Our products are widely used in the manufacture of new materials, pharmaceutical research and development and the development of new pesticides. The fluorine product categories include fluorine-containing material raw materials, fluorinated reagents, fluorine-containing building blocks, fluorine-containing reagents and fluorine-containing gases for synthesis. Shanghai Fluorine Technology will strive to build a complete industrial chain from fluorine-containing raw material procurement, fluorination technology research and development, fluorine-containing product production, fluorine-containing product storage, fluorine-containing product quality control and fluorine-containing product application.



Market News: Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly.5-Allyloxy-1H-indole-2-carboxylic acid (2-amino-phenyl)-amide manufacturer.According to Plexxikon, GSK scientists were only able to make Tafinlar after talks with Plexxikon about a potential partnership; although those talks never turned into a licensing deal, GSK apparently channeled that information and created a rival drug. o-Phenylen-(1-dimethylamino-2-butenyl)-boranat supplier The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered. (2R,3R,4S,5R,6R)-3,4,5-Tris-benzyloxy-2-benzyloxymethyl-6-dicyclohexylmethylsulfanyl-tetrahydro-pyran producer

Related Products
Product Name
7-Chloro-2-methylquinoline Cas:4965-33-7 View Details
Sodium Hydrosulfide Cas:16721-80-5 View Details
Ethanone, 1-[(2S)-tetrahydro-2-furanyl]- (9CI) Cas:131328-27-3 View Details
N-[2-Amino-4-chloro-6-[[(1R,4S)-4-(hydroxymethyl)-2-cyclopenten-1-yl]amino]-5-pyrimidinyl]formamide Cas:171887-04-0 manufacturer Dexamethasone 9,11-Epoxide Cas:24916-90-3 manufacturer 2,4-Dichloro-9,9-dimethyl-9H-fluorene Cas:1799918-67-4 manufacturer 4-Trifluoromethoxyphenylboronic acid manufacturer nicardipine hydrochloride Cas:54527-84-3 manufacturer